About Allterum
Allterum is a company based in Houston (United States) founded in 2018. Allterum has raised $65.8 million across 3 funding rounds from investors including Orbimed, Arjun Goyal and Nextech Invest. Allterum offers products and services including CD127 Monoclonal Antibody. Allterum operates in a competitive market with competitors including Poseida Therapeutics, Juno Therapeutics, TScan Therapeutics, Lyell Immunopharma and Autolus, among others.
- Headquarter Houston, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Allterum Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$65.8 M (USD)
in 3 rounds
-
Latest Funding Round
$64 M (USD), Series A
Jan 20, 2022
-
Investors
Orbimed
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Allterum
Allterum offers a comprehensive portfolio of products and services, including CD127 Monoclonal Antibody.
Targets CD127 for treating hematologic malignancies and solid tumors.
People of Allterum
Unlock access to complete
Funding Insights of Allterum
Allterum has successfully raised a total of $65.8M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $64 million completed in January 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Allterum
Allterum has secured backing from 6 investors, including angel, venture fund, and institutional investors. Prominent investors backing the company include Orbimed, Arjun Goyal and Nextech Invest.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
PE firm investing in the US
|
Locked | Locked | Locked | |
|
Biotech startups are funded by this venture capital firm.
|
Locked | Locked | Locked |
Investor details for Allterum
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Allterum
Investment portfolio details for Allterum
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Allterum
Detailed financials for Allterum
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Allterum Comparisons
Peer comparison for Allterum
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Allterum
Allterum operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Poseida Therapeutics, Juno Therapeutics, TScan Therapeutics, Lyell Immunopharma and Autolus, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| Locked | Locked | Locked |
CAR-T and TIL immunotherapies for solid tumors are developed.
|
|
| Locked | Locked | Locked |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases.
|
|
| Locked | Locked | Locked |
Developer of CAAR T cells for B cell-mediated autoimmune diseases
|
Detailed competitors of Allterum
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Allterum
Complete news archive for Allterum
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Allterum
Allterum was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Allterum is headquartered in Houston, United States. It is registered at Houston, Texas, United States.
Allterum is a funded company, having raised a total of $65.8M across 3 funding rounds to date.
Allterum was founded in 2018 in Houston, United States, within the biotechnology sector. Focus is placed on developing drugs for leukemia treatment, particularly monoclonal antibody therapies targeting pediatric acute lymphoblastic leukemia. Additional efforts involve identifying T-cell origin cancers to enable precise patient treatment. Operations center on oncology research and therapeutic innovation for hematologic malignancies.
Allterum's top competitors include Juno Therapeutics, Lyell Immunopharma and Immatics.
Allterum offers CD127 Monoclonal Antibody.
Allterum has 6 investors. Key investors include Orbimed, Arjun Goyal, Nextech Invest, Boxer Capital, and Fannin.